Skip to main content
. 2021 Nov 23;8(11):ofab502. doi: 10.1093/ofid/ofab502

Table 1.

Cohort Demographics

Characteristic Overall
(N = 204)
Cohort A
(n = 129)
Cohort B
(n = 75)
P Value
Age, y, mean (SD) 51.13 (13.83) 53.70 (12.65) 46.72 (14.71) <.001
Sex
 Female 85 (41.7) 55 (42.6) 30 (40.0) .769
 Male 119 (58.3) 74 (57.4) 45 (60.0)
Primary disease
 Acute myeloid leukemia 85 (41.7) 57 (44.2) 28 (37.3) .152
 Myelodysplastic syndrome 33 (16.2) 22 (17.1) 11 (14.7)
 Acute lymphocytic leukemia 14 (6.9) 7 (5.4) 7 (9.3)
 Non-Hodgkin lymphoma 39 (19.1) 21 (16.3) 18 (24.0)
 Multiple myeloma 7 (3.4) 3 (2.3) 4 (5.3)
 Aplastic anemia 3 (1.5) 0 (0.0) 3 (4.0)
 Solid organ malignancy 1 (0.5) 0 (0.0) 1 (1.3)
 Other 22 (10.8) 19 (14.7) 3 (4.0)
HCT conditioning
 Myeloablative 70 (34.3) 28 (21.7) 42 (56.0) <.001
 Reduced intensity 134 (65.7) 101 (78.3) 33 (44.0)
HCT source
 Matched related donor 67 (32.8) 40 (31.0) 27 (36.0) <.001
 Unrelated donor 118 (57.8) 87 (67.4) 31 (41.3)
 Haploidentical 16 (7.8) 2 (1.6) 14 (18.7)
 Cord 3 (1.5) 0 (0.0) 3 (4.0)
Unrelated donor HLA mismatch
 No (matched) 72 (61.0) 47 (54.0) 25 (80.6) .010
 Yes (mismatched) 46 (39.0) 40 (46.0) 6 (19.4)
Antithymocyte globulin
 No 94 (46.1) 48 (37.2) 46 (61.3) .001
 Yes 110 (53.9) 81 (62.8) 29 (38.7)
Post-HCT parameters
 Median days to engraftment 17 17 17 .796
 Engraftment failure >30 d 2 (1.0) 0 2 (2.7) NA
 Relapse at day 180, % (95% CI) 14.5 (10.0–19.7) 13.4 (8.1–19.9) 16.4 (8.9–25.8) .299
 Grade II–IV aGVHD at day 100, % (95% CI) 22.6 (17.1–28.5) 17.8 (11.8–24.9) 30.7 (20.6–41.4) .02

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: aGVHD, acute graft-vs-host disease; CI, confidence interval; HCT, hematopoietic cell transplant; NA, not applicable; SD, standard deviation.